Lead Product(s) : COM503
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Compugen Announces FDA Clearance of IND for COM503 for the Treatment of Solid Tumors
Details : COM503, a potential first-in-class, high affinity anti-IL-18 binding protein antibody, which is currently being evaluated for the treatment of solid tumors.
Product Name : COM503
Product Type : Antibody
Upfront Cash : Inapplicable
July 29, 2024
Lead Product(s) : COM503
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Gilead Sciences
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : COM503
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Gilead Sciences
Deal Size : $848.0 million
Deal Type : Licensing Agreement
Details : Compugen will exclusively license its potential first-in-class, pre-clinical antibody program against IL-18 binding protein, including the COM503, a potential first-in-class, high affinity antibody which blocks the interaction between IL-18 binding prote...
Product Name : COM503
Product Type : Antibody
Upfront Cash : $60.0 million
December 19, 2023
Lead Product(s) : COM503
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Gilead Sciences
Deal Size : $848.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
ImPact Biotech receives FDA Orphan Drug Designation for Padeliporfin VTP in Pancreatic Cancer
Details : Padeliporfin VTP (vascular targeted photodynamic therapy) is a minimally invasive oncology platform for the treatment of solid tumors and Pancreatic Cancer and has received Fast Track designation and Orphan Drug Designation for adult patients with low-gr...
Product Name : WST11
Product Type : Cytotoxic Drug
Upfront Cash : Inapplicable
May 07, 2023
Lead Product(s) : Padeliporfin
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radium-224
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Alpha DaRT (radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral delivery of radium-224 impregnated sources. When the radium decays it emitts high-energy alpha particles with the goal of destroyi...
Product Name : Alpha Dart
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 03, 2023
Lead Product(s) : Radium-224
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Radium-224
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Approval of IDE to Initiate Multi-Center Pivotal Study of Alpha DaRT™ in Recurrent Cutaneous SCC
Details : Alpha DaRT (Radium-224) is designed to enable highly potent and conformal alpha-irradiation of solid tumors by intratumoral insertion of radium-224 impregnated seeds.
Product Name : Alpha Dart
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 06, 2022
Lead Product(s) : Radium-224
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Allocetra,Undisclosed
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : By restoring macrophage homeostasis, Allocetra™ has the potential to provide a novel immunotherapeutic mechanism of action for life-threatening clinical indications that are defined as "unmet medical needs", as a stand-alone therapy or in combination w...
Product Name : Allocetra
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
June 06, 2022
Lead Product(s) : Allocetra,Undisclosed
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BND-22
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Sanofi
Deal Size : $1,125.0 million
Deal Type : Licensing Agreement
Details : BND-22 is a humanized IgG4, antagonist antibody targeting the Ig-like transcript 2 (ILT2) receptor in development for the treatment of solid tumors.
Product Name : BND-22
Product Type : Antibody
Upfront Cash : $125.0 million
December 01, 2021
Lead Product(s) : BND-22
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Sanofi
Deal Size : $1,125.0 million
Deal Type : Licensing Agreement
Lead Product(s) : Nam-Expanded Allogeneic NK Cell
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Gamida Cell applied the capabilities of its nicotinamide (NAM)-enabled cell expansion technology to develop GDA-201, an innate NK cell immunotherapy for the treatment of hematologic and solid tumors in combination with standard of care antibody therapies...
Product Name : GDA-201
Product Type : Cell and Gene therapy
Upfront Cash : Inapplicable
October 26, 2021
Lead Product(s) : Nam-Expanded Allogeneic NK Cell
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DSP107,Azacitidine
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Cancer Focus Fund
Deal Size : $5.0 million
Deal Type : Funding
Details : DSP107 uniquely delivers a multilayered attack by binding cancer cells and T-cells to produce a targeted synergistic effect, combining immune checkpoint inhibition with selective T-cell activation.
Product Name : DSP107
Product Type : Protein
Upfront Cash : Undisclosed
May 26, 2021
Lead Product(s) : DSP107,Azacitidine
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Cancer Focus Fund
Deal Size : $5.0 million
Deal Type : Funding
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Study Phase : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Naptumomab Estafenatox, the company’s lead TTS molecule, binds a genetically engineered bacterial determinant to the tumor surface while simultaneously activating and expanding tumor specific immune cells.
Product Name : ABR-217620
Product Type : Antibody-drug Conjugate
Upfront Cash : Inapplicable
April 19, 2021
Lead Product(s) : Naptumomab Estafenatox,Durvalumab
Therapeutic Area : Oncology
Highest Development Status : IND Enabling
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable